Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
AUSTIN, Texas, Feb. 03, 2016 -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that it will host its Analyst Day in New York, NY on Tuesday, February 23, 2016 from 8:00 AM Eastern Time to approximately 12:00 pm Eastern Time.
Christophe Lavigne, President and CEO of LDR, and other members of the executive management team will be presenting. Investors and analysts are encouraged to register in advance in order for the company to guarantee their attendance at the event. To register please contact Matthew Norman, Director, Investor Relations at [email protected].
The corporate presentation portion of the event will be webcast live and may be accessed on the Investors section of the Company’s website at www.ldr.com. For those who are not available to listen to the live webcast, the webcast replay will be archived for 12 months on LDR’s website.
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR’s primary products are based on its exclusive Mobi® non-fusion and VerteBRIDGE® fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies are designed to enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, LDR received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding and the Mobi-C Cervical Disc, visit www.ldr.com or www.cervicaldisc.com.
CONTACT:
Robert McNamara
Executive Vice President and Chief Financial Officer
LDR Holding Corporation
(512) 344-3333
Matthew Norman
Director, Investor Relations
LDR Holding Corporation
(512) 344-3408
